193 related articles for article (PubMed ID: 8823336)
1. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer.
von Tempelhoff GF; Dietrich M; Hommel G; Heilmann L
J Clin Oncol; 1996 Sep; 14(9):2560-8. PubMed ID: 8823336
[TBL] [Abstract][Full Text] [Related]
2. Effects on blood coagulation of adjuvant CNF (cyclophosphamide, novantrone, 5-fluorouracil) chemotherapy in stage II breast cancer patients.
Pectasides D; Tsavdaridis D; Aggouridaki C; Tsavdaridou V; Visvikis A; Tsatalas K; Fountzilas G
Anticancer Res; 1999; 19(4C):3521-6. PubMed ID: 10629646
[TBL] [Abstract][Full Text] [Related]
3. Level of antithrombin III, protein C, protein S and other selected parameters of coagulation and fibrinolysis in the blood of the patients with recurrent deep venous thrombosis.
Swiatkiewicz A; Jurkowski P; Kotschy M; Ciecierski M; Jawień A
Med Sci Monit; 2002 Apr; 8(4):CR263-8. PubMed ID: 11951068
[TBL] [Abstract][Full Text] [Related]
4. Blood coagulation and thrombosis in patients with ovarian malignancy.
von Tempelhoff GF; Dietrich M; Niemann F; Schneider D; Hommel G; Heilmann L
Thromb Haemost; 1997 Mar; 77(3):456-61. PubMed ID: 9065993
[TBL] [Abstract][Full Text] [Related]
5. The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer.
Demirkan B; Ozcan MA; Glu AA; Yüksel F; Undar B; Alakavuklar M
Clin Appl Thromb Hemost; 2006 Jan; 12(1):9-14. PubMed ID: 16444429
[TBL] [Abstract][Full Text] [Related]
6. [Incidence of deep venous thrombosis (DVT) in patients undergoing thoracotomy and changes of hemostasis].
Yuan XZ; Wu XM; Chen M; Yuan JY; Zhang SS
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Oct; 36(5):529-32. PubMed ID: 15489937
[TBL] [Abstract][Full Text] [Related]
7. Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer.
Paradiso A; Schittulli F; Cellamare G; Mangia A; Marzullo F; Lorusso V; De Lena M
J Clin Oncol; 2001 Oct; 19(19):3929-37. PubMed ID: 11579113
[TBL] [Abstract][Full Text] [Related]
8. A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy.
Rella C; Coviello M; Giotta F; Maiello E; Colavito P; Colangelo D; Quaranta M; Colucci G; Schittulli F
Breast Cancer Res Treat; 1996; 40(2):151-9. PubMed ID: 8879681
[TBL] [Abstract][Full Text] [Related]
9. Blood rheology during chemotherapy in patients with ovarian cancer.
von Tempelhoff GF; Niemann F; Schneider DM; Kirkpatrick CJ; Hommel G; Heilmann L
Thromb Res; 1998 Apr; 90(2):73-82. PubMed ID: 9684760
[TBL] [Abstract][Full Text] [Related]
10. D-dimer and TAT measurement in patients with deep venous thrombosis: utility in diagnosis and judgement of anticoagulant treatment effectiveness.
Speiser W; Mallek R; Koppensteiner R; Stümpflen A; Kapiotis S; Minar E; Ehringer H; Lechner K
Thromb Haemost; 1990 Oct; 64(2):196-201. PubMed ID: 2125371
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
12. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
Ottosson S; Magnusson K; Hultborn R
Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
Fumoleau P; Kerbrat P; Romestaing P; Fargeot P; Brémond A; Namer M; Schraub S; Goudier MJ; Mihura J; Monnier A; Clavère P; Serin D; Seffert P; Pourny C; Facchini T; Jacquin JP; Sztermer JF; Datchary J; Ramos R; Luporsi E
J Clin Oncol; 2003 Jan; 21(2):298-305. PubMed ID: 12525522
[TBL] [Abstract][Full Text] [Related]
14. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
French Adjuvant Study Group
J Clin Oncol; 2001 Feb; 19(3):602-11. PubMed ID: 11157009
[TBL] [Abstract][Full Text] [Related]
15. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
16. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide.
Andersen KG; Jensen MB; Kehlet H; Gärtner R; Eckhoff L; Kroman N
Acta Oncol; 2012 Nov; 51(8):1036-44. PubMed ID: 22676048
[TBL] [Abstract][Full Text] [Related]
17. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
[TBL] [Abstract][Full Text] [Related]
18. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
[TBL] [Abstract][Full Text] [Related]
19. Coagulation activation markers in the prediction of venous thrombosis after elective hip surgery.
Cofrancesco E; Cortellaro M; Corradi A; Ravasi F; Bertocchi F
Thromb Haemost; 1997 Feb; 77(2):267-9. PubMed ID: 9157579
[TBL] [Abstract][Full Text] [Related]
20. Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy.
Li H; Hu B; Guo Z; Jiang X; Su X; Zhang X
Yonsei Med J; 2019 Jan; 60(1):30-37. PubMed ID: 30554488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
